I-Mab Biopharma
IMAB
#8992
Rank
C$0.10 B
Marketcap
$1.34
Share price
-2.14%
Change (1 day)
-35.61%
Change (1 year)

Revenue for I-Mab Biopharma (IMAB)

Revenue in 2024 (TTM): C$46.37 Million

According to I-Mab Biopharma's latest financial reports the company's current revenue (TTM ) is C$50.84 Million. In 2022 the company made a revenue of -C$44.93 Million a decrease over the revenue in the year 2021 that were of C$19.31 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for I-Mab Biopharma from 2017 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) C$46.37 M
2022-C$44.93 Million-332.55%
2021C$19.31 M-94.16%
2020 C$0.33 B5407.66%
2019 C$6 M-45.08%
2018 C$10.93 M340.25%
2017C$2.48 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
C$0.31 M-99.38%๐Ÿ‡บ๐Ÿ‡ธ USA
C$1.00 B 1,870.10%๐Ÿ‡บ๐Ÿ‡ธ USA